Journal Article

Characterization of four N-3-thymidine adducts formed in vitro by the reaction of thymidine and butadiene monoxide.

R R Selzer and A A Elfarra

in Carcinogenesis

Volume 18, issue 10, pages 1993-1998
Published in print October 1997 | ISSN: 0143-3334
Published online October 1997 | e-ISSN: 1460-2180 | DOI: https://dx.doi.org/10.1093/carcin/18.10.1993
Characterization of four N-3-thymidine adducts formed in vitro by the reaction of thymidine and butadiene monoxide.

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Four products were characterized from the reaction of thymidine with butadiene monoxide (BM), a known human mutagen and possible human carcinogen. These products were purified by HPLC and characterized as diastereomeric pairs of N-3-(1-hydroxy-3-buten-2-yl)thymidine and N-3-(2-hydroxy-3-buten-1-yl)thymidine based upon their UV spectra, 1H NMR and fast atom bombardment mass spectra. Incubation of thymidine with an excess of BM at pH 7.4 and 37 degrees C allowed calculation of the pseudo-first-order kinetic rate constants for the adduct formation, but when these rate constants were compared with the rates we previously determined with guanosine, adenosine and deoxycytidine, the results suggested a lower reactivity with thymidine in comparison with the other nucleosides. When incubations were carried out at lower BM concentrations, the formation of adducts appeared to be linearly dependent on BM concentration. The four thymidine adducts were completely stable for 1 week when incubated at 37 degrees C in pH 7.4 phosphate buffer. These results suggest that the interactions of BM with thymidine may play a role in the molecular mechanisms of mutagenesis and carcinogenesis of BM.

Journal Article.  0 words. 

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.